US Pharma MarketingThe post ESC 2026: Identifying ‘silent’ atherosclerosis may help reduce global CVD burden appeared first on Medical Device Network.
ESC 2026: Identifying ‘silent’ atherosclerosis may help reduce global CVD burden
The REACT study measured silent atherosclerosis in 16,808 adults without known CVD aged 18 to 70 years old. The REACT study measured silent atherosclerosis in 16,808 adults without known CVD aged 18 to 70 years old. CVDs are the leading cause of death worldwide. Credit: studiovin/Shutterstock.com New research indicates that using imaging to detect silent atherosclerosis from early adulthood may provide an opportunity to improve primary prevention strategies and reduce the global burden of atherosclerotic cardiovascular disease (CVD). The REACT study, funded by Novo Nordisk Foundation and presented at the 2026 European Society of Cardiology (ESC) congress, taking place 28-31…
The REACT study measured silent atherosclerosis in 16,808 adults without known CVD aged 18 to 70 years old.
Source: Medical Device Network